Citation Impact
Citing Papers
Sepsis biomarkers: a review
2010 Standout
Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome
2003
Thrombin Activatable Fibrinolysis Inhibitor (TAFI) at the Interface between Coagulation and Fibrinolysis
2003
The Role of Plasminogen-Plasmin System in Cancer
2009
TAFI polymorphisms at amino acids 147 and 325 are not risk factors for cerebral infarction
2004 StandoutNobel
The metabolic syndrome
2010 Standout
Thrombin activatable fibrinolysis inhibitor (TAFI)—How does thrombin regulate fibrinolysis?
2006
Thrombin‐activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system
2003
TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a new TAFIa conformation
2011
Ophidian envenomation strategies and the role of purines
2002
Protein C levels as a prognostic indicator of outcome in sepsis and related diseases
2000
The metabolic syndrome
2005 Standout
Extracellular matrix structure
2015 Standout
Thrombin generation assays: accruing clinical relevance
2004
Autologous platelets as a source of proteins for healing and tissue regeneration
2003 Standout
Physiology and Pathophysiology of Purinergic Neurotransmission
2007 Standout
Thrombin-Activatable Fibrinolysis Inhibitor (TAFI, Plasma Procarboxypeptidase B, Procarboxypeptidase R, Procarboxypeptidase U)
2001
Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy
2009 Standout
Activity and Antigen Levels of Thrombin-Activatable Fibrinolysis Inhibitor in Plasma of Patients With Disseminated Intravascular Coagulation
2001
Pulmonary thromboembolism
2009
Effects of human soluble thrombomodulin on experimental glomerulonephritis
2002 StandoutNobel
Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays
2004
Effect of Anticoagulants in Colorimetric Assay for Basic Carboxypeptidases
2002 StandoutNobel
Platelet activation via PAR4 is involved in the initiation of thrombin generation and in clot elasticity development
2007 StandoutNobel
Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe
2002
Human and Animal Dirofilariasis: the Emergence of a Zoonotic Mosaic
2012 Standout
Preferential Detection of Pro‐Carboxypeptidase R by Enzyme‐Linked Immunosorbent Assay
2003
Heat Stability of Carboxypeptidase R of Experimental Animals
2002
Thrombin Activatable Fibrinolysis Inhibitor and an Antifibrinolytic Pathway
2000
Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis
2000
Inactivation of C3a and C5a Octapeptides by Carboxypeptidase R and Carboxypeptidase N
2002 StandoutNobel
Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Levels in Patients with Coronary Artery Disease Investigated by Angiography
2002
Chronic Thromboembolic Pulmonary Hypertension
2006 Standout
Absence of Procarboxypeptidase R Induces Complement-Mediated Lethal Inflammation in Lipopolysaccharide-Primed Mice
2004
Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets
2003
Rational Structure-Based Design of a Novel Carboxypeptidase R Inhibitor
2002 StandoutNobel
Development of a Genotype 325–Specific proCPU/TAFI ELISA
2003
Thrombin-Activatable Fibrinolysis Inhibitor Antigen Levels and Cardiovascular Risk Factors
2000
Procarboxypeptidase R Deficiency Causes Increased Lethality in Concanavalin A-Induced Hepatitis in Female Mice
2010 StandoutNobel
Two Naturally Occurring Variants of TAFI (Thr-325 and Ile-325) Differ Substantially with Respect to Thermal Stability and Antifibrinolytic Activity of the Enzyme
2002
Nanobodies: Natural Single-Domain Antibodies
2013 Standout
Molecular Cloning and Partial Characterization of Rat Procarboxypeptidase R and Carboxypeptidase N
2000 StandoutNobel
Modulation of Procarboxypeptidase R (ProCPR) Activation by Complementary Peptides to Thrombomodulin
2003 StandoutNobel
Works of K. Schatteman being referenced
The Gene for Human Carboxypeptidase U (CPU)— A Proposed Novel Regulator of Plasminogen Activation— Maps to 13q14.11
1996
Proteolytic activation of purified human procarboxypeptidase U
2000
Fast Homogeneous Assay for Plasma Procarboxypeptidase U
2001
Immunological Assay for the Determination of Procarboxypeptidase U Antigen Levels in Human Plasma
2001
Plasma Procarboxypeptidase U in Men with Symptomatic Coronary Artery Disease
2000
Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma
2003
Local proCPU (TAFI) Activation during Thrombolytic Treatment in a Dog Model of Coronary Artery Thrombosis can be Inhibited with a Direct, Small Molecule Thrombin Inhibitor (Melagatran)
2002
Activation of Plasma Procarboxypeptidase U in Different Mammalian Species Points to a Conserved Pathway of Inhibition of Fibrinolysis
1999
Assay of Procarboxypeptidase U, a Novel Determinant of the Fibrinolytic Cascade, in Human Plasma
1999